SNX20 Expression Correlates with Immune Cell Infiltration and Can Predict Prognosis in Lung Adenocarcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Shi J, Hua X, Zhu B, et al. Somatic genomics and clinical features of lung adenocarcinoma: a retrospective study. PLoS Med. 2016;13(12):e1002162. doi:10.1371/journal.pmed.1002162
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.21349
   PubMed Web of Science ®Google Scholar
• Politi K, Herbst RS. Lung cancer in the era of precision medicine. Clin Cancer Res. 2015;21:2213–2220. doi:10.1158/1078-0432.CCR-14-2748
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115‐132. doi:10.3322/caac.21338
   Web of Science ®Google Scholar
• Cullen PJ. Endosomal sorting and signalling: an emerging role for sorting nexins. Nat Rev Mol Cell Biol. 2008;9(7):574–582. doi:10.1038/nrm2427
   PubMed Web of Science ®Google Scholar
• You Y, Zhou C, Li D, et al. Sorting nexin 10 acting as a novel regulator of macrophage polarization mediates inflammatory response in experimental mouse colitis. Sci Rep. 2016;6:20630. doi:10.1038/srep20630
   PubMed Web of Science ®Google Scholar
• Bendris N, Williams KC, Reis CR, et al. SNX9 promotes metastasis by enhancing cancer cell invasion via differential regulation of RhoGTPases. Mol Biol Cell. 2016;27(9):1409–1419. doi:10.1091/mbc.E16-02-0101
   PubMed Web of Science ®Google Scholar
• Chen X, Chen S, Hang W, Huang H, Ma H. MiR-95 induces proliferation and chemo- or radioresistance through directly targeting sorting nexin1 (SNX1) in non-small cell lung cancer. Biomed Pharmacother. 2014;68(5):589–595. doi:10.1016/j.biopha.2014.04.008
   PubMed Web of Science ®Google Scholar
• Zhou Q, Huang T, Jiang Z, et al. Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway. Oncogene. 2020;39(10):2140–2155.
   PubMed Web of Science ®Google Scholar
• Schaff UY, Shih HH, Lorenz M, et al. SLIC-1/sorting nexin 20: a novel sorting nexin that directs subcellular distribution of PSGL-1. Eur J Immunol. 2008;38(2):550–564. doi:10.1002/eji.200737777
   PubMed Web of Science ®Google Scholar
• Fan L, Li L, Huang C, Huang S, Deng J, Xiong J. Increased SNX20 and PD-L1 levels can predict the clinical response to PD-1 inhibitors in lung adenocarcinoma. Onco Targets Ther. 2020;13:10075–10085. doi:10.2147/OTT.S262909
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–180. doi:10.1593/neo.07112
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–e110. doi:10.1158/0008-5472.can-17-0307
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8:740–801. doi:10.6004/jnccn.2010.0056
   PubMed Web of Science ®Google Scholar
• Wu CF, Fu JY, Yeh CJ, et al. Recurrence risk factors analysis for stage I non-small cell lung cancer. Medicine (Baltimore). 2015;94:e1337. doi:10.1097/MD.0000000000001337
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Takiguchi S, Yoshioka K, Nakabeppu Y, Itoh K. Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines. Int J Oncol. 2012;41(4):1520–1530. doi:10.3892/ijo.2012.1578
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang Z, Bao W, et al. SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC. Autophagy. 2020;16(4):735–749.
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840. doi:10.3390/ijms20040840
   PubMed Web of Science ®Google Scholar
• Oliver AJ, Lau P, Unsworth AS, et al. Tissue‐dependent tumor microenvironments and their impact on immunotherapy responses. Front Immunol. 2018;9:70. doi:10.3389/fimmu.2018.00070
   PubMed Web of Science ®Google Scholar
• Buoncervello M, Gabriele L, Toschi E. The janus face of tumor microenvironment targeted by immunotherapy. Int J Mol Sci. 2019;20(17):4320. doi:10.3390/ijms20174320
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437. doi:10.1038/nm.3394
   PubMed Web of Science ®Google Scholar
• Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor‐associated macrophage (TAM)‐targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206‐221. doi:10.1016/j.addr.2017.04.010
   PubMed Web of Science ®Google Scholar
• Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482‐1492. doi:10.1093/annonc/mdw168
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998‐2006. doi:10.1001/jama.2014.3741
   PubMed Web of Science ®Google Scholar
• Kalinski P, Talmadge JE. Tumor immuno‐environment in cancer progression and therapy. Adv Exp Med Biol. 2017;1036:1‐18.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Becht E, Fehlings M, et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557(7706):575–579. doi:10.1038/s41586-018-0130-2
   PubMed Web of Science ®Google Scholar